Moderna's data catalyst is done, and it won't get an early stop in RCC. That makes it a good short here, with the story over until at least next summer. x.com 

Moderna is a stock to bet against. x.com 

Moderna could rise further with strong call flow showing, but it is getting close to a top expected in late October or early November; take profits on the way up. x.com 

Moderna generates one-tenth of Bristol Myers Squibb's revenue, making their nearly equal valuations hard to justify. x.com 

Moderna faces about 67% downside to the Wall Street analyst price target of $50.84 per share. x.com  x.com 

Moderna could get explosive above $200 as anyone who shorted last week's valuation downgrade has to cover. The shakeout on that downgrade was a killer opportunity, and the stock is now back over $200. x.com 

Moderna has almost 40% downside to its average analyst price target of $119.56, which makes the sudden rush to buy it hard to explain. x.com 

Moderna's customer options positioning was not bullish, and the stock subsequently flushed 20%. WizOfOps described the top 10 trades as only modestly bearish, with no solid consensus among the customers dominating the flow. x.com 

Moderna could re-rate toward $210 by the end of 2027 because the market should move ahead of its free cash flow inflection. That assumes free cash flow reaches breakeven by mid-2028, driven by successful commercialization of its personalized mRNA cancer therapy. x.com 

Moderna remains unattractive despite forced Nasdaq-100 index buying: quarterly revenue is $145M against a $782M loss, while shares trade around $200. Citi rates it Sell with an $80 target. x.com